Bio-Rad Laboratories Upgraded to “Neutral” at Zacks (BIO)
Zacks upgraded shares of Bio-Rad Laboratories (NYSE:BIO) from an underperform rating to a neutral rating in a research note issued to investors on Tuesday. The firm currently has $120.20 price target on the stock.
Bio-Rad Laboratories (NYSE:BIO) traded down 0.07% during mid-day trading on Tuesday, hitting $117.96. 21,419 shares of the company’s stock traded hands. Bio-Rad Laboratories has a 52 week low of $113.02 and a 52 week high of $134.13. The stock’s 50-day moving average is $120.5 and its 200-day moving average is $124.. The company has a market cap of $3.399 billion and a P/E ratio of 53.20.
Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Tuesday, May 6th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.80 by $0.57. The company had revenue of $509.30 million for the quarter, compared to the consensus estimate of $515.00 million. During the same quarter in the previous year, the company posted $0.68 earnings per share. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, analysts predict that Bio-Rad Laboratories will post $3.86 earnings per share for the current fiscal year.
Separately, analysts at TheStreet downgraded shares of Bio-Rad Laboratories from a buy rating to a hold rating in a research note on Monday, May 26th.
Bio-Rad Laboratories, Inc (NYSE:BIO), manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
To view Zacks’ full report, visit Zacks’ official website.
Stay on top of analysts' upgrades and downgrades with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' ratings changes. Register Now.